We are live on ! Find out more
BIOS

BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS

Delisted

BIOS was delisted on the 6th of October, 2023.

Back to rankings

65 hedge funds and large institutions have $193M invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

14% more funds holding

Funds holding: 57 → 65 (+8)

8% more capital invested

Capital invested by funds: $179M → $193M (+$14.1M)

Holders
65
Holders Change
+8
Holders Change %
+14.04%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
13
Reduced
7
Closed
6
Calls
$101K
Puts
–
Net Calls
+$101K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$4.02M
2
CF
Cantor Fitzgerald
New York
+$2.98M
3
SCM
Saba Capital Management
New York
+$2.5M
4
HCM
Highbridge Capital Management
New York
+$2.24M
5
HSBC Holdings
HSBC Holdings
United Kingdom
+$1.44M

Top Sellers

Rank Fund Capital Flow
1
DKCM
Davidson Kempner Capital Management
New York
-$2.48M
2
BCM
Beryl Capital Management
California
-$2.47M
3
WAM
Wolverine Asset Management
Illinois
-$2.4M
4
WAM
Weiss Asset Management
Massachusetts
-$1.44M
5
FLC
Fifth Lane Capital
Texas
-$1.01M

BIOS Hedge Fund Activity: Q2 2022 in Review

65 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q2 2022, worth a combined $193M — up 7.9% from $179M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new BIOS positions and 6 closed out — a net gain of 8 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was Mangrove Partners, opening a new position worth an estimated $4.02M. The largest seller was Davidson Kempner Capital Management, cutting an estimated $2.48M.

  • 65 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q2 2022, up from 57 in Q1 2022.
  • Funds reported $193M of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q2 2022, up 7.9% quarter-over-quarter.
  • 14 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q2 2022 and 6 closed out, a net change of +8 holders.
  • The largest BioPlus Acquisition Corp. Class A Ordinary Shares buyer in Q2 2022 was Mangrove Partners, an estimated $4.02M added.
  • The largest BioPlus Acquisition Corp. Class A Ordinary Shares seller in Q2 2022 was Davidson Kempner Capital Management, an estimated $2.48M sold.

Based on aggregated 13F filings for Q2 2022.